Paul Thompson
Oprichter bij Padlock Therapeutics, Inc.
Profiel
Paul Thompson is the founder of Padlock Therapeutics, Inc. He is currently working as a Professor & Director-Chemical Biology at the University of Massachusetts Medical School.
He completed his undergraduate and doctorate degrees from McMaster University.
Actieve functies van Paul Thompson
| Bedrijven | Functie | Begin |
|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Oprichter | - |
| UMass Chan Medical School | Corporate Officer/Principal | - |
Opleiding van Paul Thompson
| McMaster University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
